BRPI1012219B8 - produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina - Google Patents

produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina Download PDF

Info

Publication number
BRPI1012219B8
BRPI1012219B8 BRPI1012219A BRPI1012219A BRPI1012219B8 BR PI1012219 B8 BRPI1012219 B8 BR PI1012219B8 BR PI1012219 A BRPI1012219 A BR PI1012219A BR PI1012219 A BRPI1012219 A BR PI1012219A BR PI1012219 B8 BRPI1012219 B8 BR PI1012219B8
Authority
BR
Brazil
Prior art keywords
product
antimicrobial peptide
cysteamine
environment
substrate
Prior art date
Application number
BRPI1012219A
Other languages
English (en)
Inventor
Charrier Cedric
O' Neil Deborah
Mercer Derry
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of BRPI1012219A2 publication Critical patent/BRPI1012219A2/pt
Publication of BRPI1012219B8 publication Critical patent/BRPI1012219B8/pt
Publication of BRPI1012219C1 publication Critical patent/BRPI1012219C1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • A01N33/08Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254Enzymes, proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424Anti-adhesion agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures

Abstract

produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina a presente invenção refere-se a um produto compreendendo pelo menos dois agentes anti-biofilme sendo que pelo menos um dos agentes anti-biofilme é um peptídeo antimicrobiano. o segundo agente anti-biofilme é geralmente um dispersante ou um agente anti-adesivo. proporciona-se também o uso do produto no tratamento de uma infecção microbiana.
BRPI1012219A 2009-03-31 2010-03-31 produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina BRPI1012219C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16539609P 2009-03-31 2009-03-31
GBGB0905451.1A GB0905451D0 (en) 2009-03-31 2009-03-31 Biofilms
PCT/GB2010/000631 WO2010112848A2 (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms

Publications (3)

Publication Number Publication Date
BRPI1012219A2 BRPI1012219A2 (pt) 2016-03-29
BRPI1012219B8 true BRPI1012219B8 (pt) 2020-05-12
BRPI1012219C1 BRPI1012219C1 (pt) 2021-05-25

Family

ID=40671951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012219A BRPI1012219C1 (pt) 2009-03-31 2010-03-31 produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina

Country Status (21)

Country Link
US (3) US9339525B2 (pt)
EP (1) EP2413949B1 (pt)
JP (1) JP5727994B2 (pt)
KR (1) KR101852784B1 (pt)
CN (2) CN104257645A (pt)
AU (2) AU2010231136B2 (pt)
BR (1) BRPI1012219C1 (pt)
CA (1) CA2755878C (pt)
CY (1) CY1121175T1 (pt)
GB (1) GB0905451D0 (pt)
IL (1) IL215369B2 (pt)
MX (1) MX358018B (pt)
NZ (1) NZ595037A (pt)
PL (1) PL2413949T3 (pt)
RU (1) RU2548786C2 (pt)
SG (2) SG10201400926VA (pt)
SI (1) SI2413949T1 (pt)
TR (1) TR201821161T4 (pt)
UA (1) UA106743C2 (pt)
WO (1) WO2010112848A2 (pt)
ZA (1) ZA201107140B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112008001301T5 (de) 2007-05-14 2010-04-29 Reserach Foundation Of State University Of New York Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
TWI403330B (zh) * 2010-03-29 2013-08-01 Rise technology co ltd 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
GB201016733D0 (en) * 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
EP2707019B1 (en) 2011-05-12 2016-06-29 Smith & Nephew Orthopaedics AG Wound debridement compositions containing seaprose and methods of wound treatment using same
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用1,2,3,4,6-五-o-沒食子醯基-d-葡哌喃糖來抑制生物膜形成
WO2013076666A1 (en) * 2011-11-23 2013-05-30 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
IN2014DN08299A (pt) * 2012-03-23 2015-05-15 Amicrobe Inc
MX2014013745A (es) 2012-05-11 2016-05-05 Smith & Nephew Inc Uso de seaprose para eliminar la pelicula biologica bacteriana.
WO2014016979A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物活性調節剤及び微生物の活性を調節する方法
CA2922516A1 (en) * 2013-08-27 2015-03-19 The University Of British Columbia Small cationic anti-biofilm and idr peptides
GB201405891D0 (en) * 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
US11103547B2 (en) 2016-02-04 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
US20210213096A1 (en) * 2016-02-19 2021-07-15 Forschungszentrum Borstel Leibniz-Zentrum Fur Medizin Und Biowssenschaften Means and methods for treating bacterial infections
US11207378B2 (en) 2016-04-04 2021-12-28 University Of Virginia Patent Foundation Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
EP3241570A1 (en) * 2016-05-02 2017-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide and hyaluronic acid coatings
CN109789191B (zh) * 2016-05-12 2023-08-01 宾夕法尼亚州立大学托管会 用于抑制生物膜沉积和产生的组合物和方法
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
LT3554491T (lt) 2016-12-15 2023-05-25 Zambon S.P.A. N-acetilcisteinas, skirtas naudoti kaip antibakterinis agentas
AU2017381394A1 (en) * 2016-12-22 2019-07-25 The University Of Sydney Biofilm disrupting composition
US20180184656A1 (en) * 2017-01-05 2018-07-05 Cormedix Inc. Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
AU2018249552A1 (en) 2017-04-06 2019-10-31 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
CN108048359B (zh) * 2017-12-27 2020-12-01 广州立白企业集团有限公司 一种牙菌斑生物膜模型的培养方法和优化的生物膜活菌计数法及应用
WO2019178274A1 (en) * 2018-03-13 2019-09-19 Peptilogics, Inc. Treatment of implants with engineered antimicrobial amphiphilic peptides
CN108753632A (zh) * 2018-05-25 2018-11-06 安徽中医药大学 一种溶解白念珠菌生物被膜胞外基质的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020079186A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
CN110402928A (zh) * 2019-08-08 2019-11-05 杭州博菲医疗器械有限公司 一种抑菌功能液及应用该抑菌功能液的导管组件
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
CN111675751B (zh) * 2020-04-08 2022-06-14 天津医科大学口腔医院 一种抗菌肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US6475434B1 (en) * 1998-12-07 2002-11-05 Baylor College Of Medicine Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN103360485A (zh) * 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
US20070093894A1 (en) * 2005-10-25 2007-04-26 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
ZA200805191B (en) * 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
WO2009023356A2 (en) * 2007-05-25 2009-02-19 Omega-Biopharma (H.K.) Limited Materials and methods for treating influenza infections
US20090209650A1 (en) * 2008-02-17 2009-08-20 Francis Chi Materials and Methods for Improving the health of Shrimp
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20160106689A1 (en) * 2014-09-22 2016-04-21 Novabiotics Limited Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds

Also Published As

Publication number Publication date
CY1121175T1 (el) 2020-05-29
AU2010231136B2 (en) 2016-08-04
CN102387794B (zh) 2015-11-25
CA2755878C (en) 2018-04-24
US20120189682A1 (en) 2012-07-26
NZ595037A (en) 2013-07-26
SI2413949T1 (sl) 2019-02-28
KR101852784B1 (ko) 2018-04-30
US9339525B2 (en) 2016-05-17
MX358018B (es) 2018-08-02
IL215369B (en) 2022-10-01
EP2413949B1 (en) 2018-10-10
WO2010112848A2 (en) 2010-10-07
US20160206575A1 (en) 2016-07-21
TR201821161T4 (tr) 2019-01-21
MX2011010258A (es) 2011-10-19
EP2413949A2 (en) 2012-02-08
IL215369A (en) 2013-02-03
SG174278A1 (en) 2011-10-28
BRPI1012219A2 (pt) 2016-03-29
AU2016210742B2 (en) 2017-08-10
GB0905451D0 (en) 2009-05-13
AU2016210742A1 (en) 2016-08-25
CA2755878A1 (en) 2010-10-07
JP5727994B2 (ja) 2015-06-03
UA106743C2 (uk) 2014-10-10
SG10201400926VA (en) 2014-10-30
AU2010231136A1 (en) 2011-09-29
RU2548786C2 (ru) 2015-04-20
PL2413949T3 (pl) 2019-04-30
IL215369B2 (en) 2023-02-01
JP2012522037A (ja) 2012-09-20
CN102387794A (zh) 2012-03-21
BRPI1012219C1 (pt) 2021-05-25
WO2010112848A3 (en) 2011-01-27
CN104257645A (zh) 2015-01-07
US20190175528A1 (en) 2019-06-13
KR20120003893A (ko) 2012-01-11
ZA201107140B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
BRPI1012219B8 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112013005426A2 (pt) &#34;composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação.&#34;
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
MX2017004091A (es) Composicion y equipos para inhibicion de infeccion microbiana patogena y metodos para usar los mismos.
BR112014012689A2 (pt) montagem e método de uso de um cateter e método para administração de uma composição antimicrobiana
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR112012006010A2 (pt) composto de glicina
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BRPI0916885B8 (pt) composição farmacêutica
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
BR112017020796A2 (pt) compostos, composição farmacêutica e kit
CO2022000270A2 (es) Inhibidores de enzimas
BR112015032284A2 (pt) dispositivo médico compreendendo colágeno-vi
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
MX2013005182A (es) Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
BR112015027984A2 (pt) Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
BR112014012966A2 (pt) método para o controle da proliferação de pseudomonas; e uso de um agente de desinfecção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2573 DE 28/04/2020 QUANTO AO TITULO E A PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF